All Industries

Dogecoin News: Will DOGE Reach $1 Before The Ethereum Price Reaches $7,000?

Cutoshi

With Bitcoin reaching a new all-time high, Ethereum (ETH) and Dogecoin (DOGE) are climbing too. The rise in prices is real. Now, analysts are looking at which one will reach key price points next. Ethereum's Bullish Momentum DeFi giant Ethereum (ETH) has seen a slow performance this year, but its momentum is now picking up. Currently, it is trading at $3,929, with a year-to-date rise in price by 75%. A part of this growth is due to the overall market momentum, as well as changing sentiment around Ethereum itself. Regulatory changes in the US are significantly impacting its appeal. With crypto going increasingly mainstream, Ethereum is a favorite for institutions, after Bitcoin. This is why Ethereum ETFs have seen record inflows in the past month, together with Bitcoin ETFs. The influx of institutional money is bound to push Ethereum up significantly in the coming months. Analysts are predicting Ethereum to reach $4,500 in one month. If it manages to break this key resistance, its potential is even higher. What is more, the recent rally focused particularly on DeFi tokens and Ethereum is the largest among them. For this reason, if Ethereum manages to stay above its key level of $4,500, it could reach $7,000 in three months. Dogecoin's Rise In Popularity Dogecoin (DOGE), Elon Musk’s favorite meme coin, is quickly getting attention once again. Traders are now looking at a potential repeat of the 2021 price surge. At the time, DOGE reached its ATH after the GameStop saga, fueled by retail traders and Musk’s constant tweets. Currently, DOGE is priced at $0.4108 after dancing around the $0.4 mark for the past month. This is a significant level, reached after the November election, carrying it from $0.1. What carried its growth was Elon Musk’s position in Trump’s coming administration. Traders expect Musk will not miss an opportunity to use his new high-profile position to promote Doge. In fact, Musk has already named its Department of Government Efficiency (DOGE) after the token. Still, a $1 price target is ambitious for Dogecoin. How quickly it attains this level will likely depend on whether the meme coin markets heat up again. In that scenario, Dogecoin could reach $1 in two months. Cutoshi Unites Both Memes And Utility Whether Dogecoin or Ethereum wins out in this race depends largely on markets favoring either memes or utility. However, one token will likely do well in both scenarios. MemeFi Cutoshi (CUTO) is a unique blend of memes and utility, appealing to both types of traders. Recently, Cutoshi broke a key milestone, reaching $1.37 million in presale investments. Once the presale is over, the token will be listed on major exchanges, with more opportunity for growth. The key behind Cutoshi’s viral status is its appeal to both DeFi traders and memecoin investors. It is both a meme coin and a DeFi ecosystem, complete with a multichain DEX, a learning platform and more. This way, Cutoshi hopes to use memes to attract users to DeFi and educate them about its benefits. With more and more users that understand the importance of self-custody and decentralization, projects like Cutoshi have a real chance to grow the DeFi industry. For more information on the Cutoshi (CUTO) Presale: https://cutoshi.com/ Join and become a community member: https://twitter.com/CutoshiToken https://t.me/cutoshi Welcome to Cutoshi, the revolutionary meme coin, DeFi hub and educational platform inspired by the Lucky Cat and Satoshi Nakamoto’s teachings. Traditionally, people put the Lucky Cat in their homes and businesses to maximize its lucky powers and bring them good fortune and wealth. Now Cutoshi the Lucky Cat is on the blockchain bringing luck, prosperity, and wealth to your digital assets. Cutoshi is creating a path to financial freedom, for those who choose to honor the power of the Lucky Cat. Supporting the principles of freedom, privacy, anonymity, and monetary empowerment for the masses. Cutoshi aims to bring the benefits of blockchain to everyone. The regulatory environment surrounding cryptocurrencies is evolving and varies across jurisdictions. It is your responsibility to ensure compliance with applicable laws and regulations in your country or region before engaging with Custoshi. Contact Details Cutoshi hello@cutoshi.com Company Website https://cutoshi.com/

December 21, 2024 10:23 AM Eastern Standard Time

Image

News Release

5thScape Announces Highly-Anticipated Crypto Listing in January 2025

Spark Metro PR

5thScape, a trailblazing platform that combines virtual reality (VR) with blockchain technology, is set to make waves in the cryptocurrency world with its much-awaited 5SCAPE token listing on major exchanges in January 2025. This landmark event signals a turning point for VR enthusiasts, blockchain adopters, and early investors looking to capitalize on the future of immersive technology. Expanding Ecosystem: Proprietary hardware and game rollouts solidify 5thScape’s dominance in the market. 5thScape: A Game-Changer in VR and Blockchain As the lines between virtual and digital worlds blur, 5thScape positions itself as a frontrunner in delivering cutting-edge VR experiences powered by a seamless blockchain ecosystem. By integrating proprietary VR hardware, an ever-expanding catalog of immersive games, and the powerful 5SCAPE token, 5thScape is setting the standard for innovation in tech. Key Features of 5thScape: Diverse VR Game Library: Titles like MMA Cage Conquest, Epic Cricket Arena, and Thrust Hunter redefine immersive gameplay. Proprietary VR Hardware: Revolutionary products like the VR Ultra Headset and SwiftScape VR Chair enhance user comfort and gameplay intensity. Developer Hub: A centralized platform for VR developers to create, launch, and monetize content within the ecosystem. 5SCAPE Token: The backbone of the platform, enabling access to premium content, governance participation, and staking opportunities. January 2025 Listing: A Milestone for 5thScape Since its launch, 5thScape has captured global attention, raising over $8 million during its presale and attracting a community of over 30,000 early investors. The highly anticipated token listing in January 2025 is set to unlock new opportunities for growth, global adoption, and increased token value. “We’re thrilled to announce the public listing of 5SCAPE tokens. This is a defining moment for 5thScape as we bridge the gap between VR and blockchain,” said Anoj Kumar (CEO). “With unparalleled support from our community, we’re set to redefine the standards of virtual interaction and crypto utility.” Why the 5SCAPE Token Listing Is Significant The upcoming listing is more than just a market launch—it’s a catalyst for mainstream adoption of VR and blockchain technology. Early investors stand to benefit from the token's projected demand surge and ecosystem expansion. Investor Benefits: First-Mover Advantage: Access the token before widespread market adoption. Limited Supply: A capped supply of 5.21 billion tokens ensures scarcity-driven value. Strong Market Potential: Leveraging continued hardware and game development, 5thScape promises sustained growth and engagement. Global Anticipation and Market Potential With a firm foothold in VR innovation, 5thScape is carving its niche as a top blockchain-powered VR platform. The listing will not only enhance liquidity and accessibility for the 5SCAPE token but also fuel its growing ecosystem. Projected Market Impact: Increased Adoption: Broader exposure to gaming, education, and entertainment industries. Enhanced Token Value: Anticipated demand shocks following the listing are expected to drive value appreciation. Expanding Ecosystem: Proprietary hardware and game rollouts solidify 5thScape’s dominance in the market. 5thScape is a next-generation platform that combines virtual reality (VR) and blockchain technology to create an ecosystem for gaming, education, and entertainment. Powered by the 5SCAPE token, the platform offers access to premium VR content, developer tools, and community-driven initiatives. With the January 2025 listing just weeks away, the opportunity to join the 5thScape ecosystem at presale prices is closing fast. Don’t miss your chance to invest in the platform poised to reshape the VR and blockchain landscapes. Visit the 5thScape official website to secure your tokens today. About 5thScape 5thScape is a next-generation platform that combines virtual reality (VR) and blockchain technology to create an ecosystem for gaming, education, and entertainment. Powered by the 5SCAPE token, the platform offers access to premium VR content, developer tools, and community-driven initiatives. Contact Details 5thScape 5thScape Team +1 302-597-6768 Company Website https://5thscape.com/

December 21, 2024 08:37 AM Eastern Standard Time

African American Heritage Brands Black Radiance and Cross Colours Join Forces For Retro Beauty Collaboration

Black Radiance Beauty

Black Radiance, the leading beauty brand for women of color, has teamed up with Cross Colours, the Afro-centric streetwear brand that embodies the bold spirit of retro hip-hop culture, for an exciting first-ever collaboration. This partnership brings together two trailblazing brands with deep roots in African American culture, uniting to honor their shared heritage by reimagining the bold, expressive spirit of the 80s and 90s hip-hop culture through innovative makeup design. With over 30 years of shaping beauty and fashion for the African American community, the collection draws inspiration from Cross Colours' vibrant color aesthetic, capturing the essence of the hip-hop era. Together, the brands are celebrating a time when music, fashion, and beauty pushed boundaries and defined an era. "This partnership is a full-circle moment for Black Radiance," said K. MacDonald Parris, Vice President of Marketing at Black Radiance. “We are thrilled to work with the iconic label that helped shape hip-hop culture and revolutionized streetwear just as we’ve redefined beauty for Black women. Now, we’ve come together to honor that era and bring it into today’s digital and social world, creating bold new beauty moments that resonate with both the original generation and today’s youth." “We’ve always seen makeup artists creating incredible looks inspired by Cross Colours,” said TJ Walker, Co-Founder of Cross Colours. “That creativity inspired us to give something back to the beauty community, something that reflects the spirit of individuality and self-expression that Cross Colours was built on. Black Radiance shares this passion for celebrating authenticity, making this collaboration feel so natural." “The retro theme of this collection pays homage to the era that birthed our brands and celebrates the deep connection between music, fashion, and beauty,” said Carl Jones, Co-Founder of Cross Colours. “This collection is a celebration of Black beauty in all its forms—it’s about empowerment, individuality, and embracing who you are. Through this collaboration, we continue our commitment to uplifting Black women and redefining beauty standards.” The Black Radiance X Cross Colours collection includes: Cross Colours™ Eye Shadow Palette ($15): A cassette tape-inspired palette with eight talc-free, pigment-rich powders in matte, metallic, and shimmer finishes for bold, vibrant eye looks. Cross Colours™ Mic Drop Mascara ($12): This volume-boosting mascara delivers intense color, featuring a 500+ bristle-packed hourglass brush for clump-free definition. Available in Check 1 Black and Check 2 Blue. Cross Colours™ Paint Palette ($10): A multi-use palette with four creamy, blendable primary colors enriched with Vitamin E and Soybean oil for vibrant face and eye looks. Cross Colours™ Metallic Liquid Lip ($8): A glossy long-wearing formula with bold metallic hues and multidimensional shine, available in Fresh Drip Pink, Vixen Red, and Hyped Up Purple. Cross Colours™ Lipstick Remix ($10): A creamy, ombre-effect lipstick with Murumuru Butter, Vitamin E, and botanical oils for soft, sculpted lips. Available in Gimme A Beat, 3 Divas, and Triple Threat. The Black Radiance x Cross Colours collaboration will be available to shop online at Amazon and select CVS, Target, Walgreens, and Walmart stores. Be sure to follow every Black Radiance x Cross Colours moment on Black Radiance’s Instagram, Facebook, Twitter, and TikTok, and Cross Colours’ Instagram, Facebook, and Twitter. High res images, interviews, and media samples are available upon request. About Black Radiance: For over 30 years, Black Radiance® has recognized, represented, and celebrated the diversity of darker complexions by offering affordable, high-quality cosmetics with uncompromising color, trusted coverage, and formula innovation. Black Radiance empowers and inspires women of color through cosmetics, beauty, and lifestyles. Our mission – to enable Black women worldwide to be even more beautiful. We promise to create both products and experiences that encourage women of color worldwide to embrace, enhance, define, and love their shade of beauty. About Cross Colours: Founded in 1989 by Carl Jones and TJ Walker, Cross Colours revolutionized fashion with its vibrant, socially conscious designs deeply rooted in hip-hop culture. Championing "Clothing Without Prejudice," the brand has been a beacon for Pan-Africanism and Afrocentrism, worn by icons like Will Smith, TLC, and more recently, Rihanna and Cardi B. As the first Black-owned brand to hit $100 million in sales and achieve mass distribution, Cross Colours continues to inspire and empower a new generation, maintaining its commitment to inclusivity and cultural expression. For more information, visit crosscolours.com or follow us @crosscoloursla on Instagram and TikTok. Contact Details Six One Agency Camryn Carlson camryn@six-one.com Black Radiance Sherry West swest@markwins.com

December 20, 2024 10:07 AM Eastern Standard Time

Image

Market Alert: Actelis Networks Introduces MetaShield, Pioneering AI Solutions for Critical Infrastructure Protection (NASDAQ: ASNS)

Global Markets News

Actelis Networks (NASDAQ: ASNS) has just announced the launch of MetaShield, a groundbreaking AI-based cybersecurity solution poised to redefine security protocols for IoT and critical infrastructure networks. This pivotal is representative exemplifies Actelis' visionary approach and marks a significant leap forward in its mission to enhance networks across the globe, setting a new standard in creating robust and secure IoT networks and achieving critical infrastrucutre modernization. Addressing Growing Threats to Critical Infrastructure The introduction of MetaShield is particularly significant as it directly responds to the increasing frequency and sophistication of cyber threats targeting critical infrastructure. With cyberattacks on essential systems reportedly surging by 30% in 2023, organizations across sectors are under immense pressure to bolster their defenses. MetaShield’s advanced capabilities, including real-time anomaly detection and AI-driven threat mitigation, empower Actelis to offer a proactive solution that not only secures networks but also safeguards vital operations. This focus on protecting critical infrastructure aligns Actelis with the urgent needs of governments and industries, positioning it as a trusted partner in enhancing national and operational security. Expanding Opportunities for Upselling MetaShield is not just a standalone product; it represents a strategic opportunity for Actelis to deepen its relationships with existing clients and explore upselling potential. As organizations adopt MetaShield, Actelis can leverage this integration to provide additional services and upgrades, enhancing customer loyalty and increasing revenue per client. This ability to deliver comprehensive, layered security solutions creates a compelling value proposition, ensuring that Actelis remains indispensable to its clients' operational needs. A Lean and Growing Software Business Model The launch of MetaShield signifies a critical step towards a growing Software as a Service (SaaS) model that can drive recurring revenue and solidify Actelis’ position within the cybersecurity sector. By establishing a lean, software-focused business model, Actelis is positioned to capitalize on the growing demand for subscription-based cybersecurity solutions. This shift may not only only enhances the financial position in the long term, but also aligns with broader industry trends where clients prefer flexible, scalable solutions that adapt to their evolving security needs. Moreover, the ongoing software revenue stream may further allow Actelis to invest in continuous innovation and development, ensuring that its solutions remain at the forefront of cybersecurity technology. As the market for cybersecurity solutions continues to expand, Actelis' commitment to a growing software business model will be essential for long-term success and competitiveness. A New Era for Actelis Networks In summary, the announcement of MetaShield marks a revolutionary step for Actelis Networks, showcasing its commitment to innovation and leadership in the cybersecurity landscape. By addressing the urgent needs for robust security in critical infrastructure, creating upselling opportunities, and transitioning to a lean software business model, Actelis is exceptionally well-positioned to meet the growing demand for integrated security solutions. The launch of MetaShield could not only elevate Actelis' market position but also reinforce the resilience of critical infrastructure in an interconnected world. This launch is not just a new product; it may very well be the start of a transformative chapter for Actelis Networks as it aims to shape the future of cybersecurity. Read Actelis Networks' Latest Announcements * * * * This news alert may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Companies in emerging industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This news alert was issued by Global Markets Media, a commercial digital brand operated for IR purposes who's operators are compensated by actelis for coverage and distribution services. The above content is for informational purposes only and it is not intended to serve as financial or investment advice and this constitutes an advertisement for the purposes of section 17(b) of the securities act. Please review the full disclaimers and disclosures detailing conflicts of interest [https://justpaste.it/ecto7/pdf]. Contact Details Global Markets News Desk ronald@futuremarketsresearch.com

December 20, 2024 09:00 AM Eastern Standard Time

Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial

Benzinga

By Meg Flippin, Benzinga Cognition Therapeutics Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including dementia with Lewy bodies (DLB), announced positive topline results of its exploratory phase 2 SHIMMER study for CT1812, its experimental orally delivered small molecule oligomer antagonist to treat this progressive form of dementia. Cognition Therapeutics said the trial demonstrated CT1812 produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with DLB. DLB is a form of dementia in which symptoms come on fast. DLB can quickly lead to a decline in thinking and reasoning as well as independent movements, and can cause uncontrollable changes in alertness, recurring hallucinations, sleep disruptions, tremors and slow movement. It impacts about 1.4 million people in the U.S. and is the costliest form of dementia. As it stands, drugs to cure this debilitating form of dementia are nonexistent, and treatments, which are used off-label focus on managing symptoms. Promise In A Pill “These topline results exceeded our expectations and support the broad potential of CT1812 across neurodegenerative disorders,” Anthony Caggiano, M.D., Ph.D., Cognition’s chief medical officer and head of R&D, said when announcing the results. “Analysis of CT1812’s activity in DLB will continue as additional data become available. We look forward to reporting these findings at future medical meetings and reviewing them with the FDA in an end-of-phase 2 meeting.” The phase 2 SHIMMER study enrolled 130 adults who were randomized to receive either placebo or one of two oral once-daily doses of CT1812 (100 mg or 300 mg) for six months. Participants were assessed throughout the study using the Montreal Cognitive Assessment (MoCA) and Cognitive Drug Research (CDR) Battery, which track cognitive performance; the Clinician Assessment of Fluctuation (CAF) to measure the frequency and duration of cognitive fluctuations; and the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part III, an objective assessment of parkinsonism. Cognition Therapeutics said the study met its primary endpoint of safety and tolerability, with data showing that DLB patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive and movement measures compared to the placebo. Cognition reported an 82% slowing in the total neuropsychiatric inventory (NPI), with a particularly strong reduction in anxiety, hallucinations and delusions in the CT1812 treated arms. In addition, there was a marked reduction in caregiver distress, which suggests a positive impact on the day-to-day lives of those receiving the drug, reports the company. Participants treated with CT1812 experienced a slowing of decline across all three cognitive measures compared to the placebo, including fluctuations in attention which declined by 91%. Cognition plans to present detailed data at the International Lewy Body Dementia Conference (ILBDC) in January 2025. The SHIMMER study is supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million and is being conducted in collaboration with the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and the Lewy Body Dementia Association (LBDA). Preceding Trial Had Promising Results Cognition had previously completed a Phase 2 SHINE study to look at CT1812’s effects on treating individuals aged 50 to 85 who have mild-to-moderate Alzheimer’s disease. That study recruited 153 individuals, and the results showed a 95% slowing of cognitive decline in people exhibiting a key Alzheimer’s disease biomarker. “With the SHIMMER and SHINE results, we are confident in CT1812’s clinical activity given that it has demonstrated broad neurologic and neuroprotective activity in DLB and Alzheimer’s disease,” Lisa Ricciardi, Cognition’s president and CEO, said. “People with these diseases, particularly DLB, have few therapeutic options leading to a cascade of symptoms that are painful to the individual and their caregivers. We are eager to continue the development of CT1812 in late-stage clinical trials with the hope of providing a once-daily pill that can treat these devastating neurodegenerative conditions.” To learn more about Cognition Therapeutics and its SHIMMER study, click here. Featured photo by Rad Cyrus on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 20, 2024 08:35 AM Eastern Standard Time

Image

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Benzinga

By Meg Flippin, Benzinga Mainz Biomed N.V. (NASDAQ: MYNZ), the molecular genetics diagnostic company specializing in the early detection of cancer, is moving closer to commercializing its early colorectal cancer detection screening ColoAlert® in the U.S. by inking deals with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services. As part of the agreements, Mainz Biomed said Quest Diagnostics will provide clinical trial and laboratory services to support its ReconAAsense Food and Drug Administration pivotal study of ColoAlert. The clinical trial is slated to kick off next year with up to 15,000 patients. If ColoAlert gets the nod from the U.S. FDA, it will be able to target the millions of Americans at risk of colorectal cancer. Mainz has said its commercial strategy is to establish scalable distribution in the U.S. through a collaborative partner program with regional and national laboratory service providers. The recent strategic alliance with Thermo Fisher Scientific (NYSE: TMO), a global leader in life sciences with annual revenue exceeding $40 billion, represents a monumental step forward in transforming cancer prevention in the United States, says Mainz. This partnership harnesses Thermo Fisher's extensive expertise and state-of-the-art infrastructure to drive innovation in healthcare solutions. Adding further depth to this initiative is the collaboration with Quest Diagnostics, a leader in advanced testing and sampling technologies. Quest Diagnostics offers a broad range of services, including routine blood work, genetic and molecular testing and specialized diagnostic services for various diseases, such as cancer, cardiovascular conditions and infectious diseases. Mainz reports that Quest Diagnostics is widely recognized for its national network of laboratories, extensive patient service centers and cutting-edge technology that ensures accurate and timely test results. As a significant player in the healthcare industry, particularly in diagnostic testing and sampling, Quest Diagnostics serves millions of patients and healthcare providers annually, making it a critical component in advancing precision and scalability in early cancer detection and prevention. With $8 million in funding dedicated to expediting FDA approval, this initiative aims to rapidly advance critical milestones, laying the groundwork for massive expansion. Together, Mainz believes these partnerships are poised to catalyze a sweeping transformation in public health outcomes, creating a tidal wave of innovation and economic growth that will ripple across the healthcare landscape. Readying ColoAlert For Potential U.S. Debut In addition to supporting the clinical trial, Mainz said Quest Diagnostics has a semi-exclusive right to market ColoAlert in the U.S. for an eighteen-month period. If exercised, this option will allow Quest Diagnostics the opportunity to offer the product to multiple channels, including physicians, health systems, hospitals, health plans, employers and consumers, reports Mainz Biomed. “We are excited by the opportunity to collaborate with Quest Diagnostics,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Teaming with Quest Diagnostics during our critical FDA Study will be key to our long-term success.” Encouraging Trial Results ColoAlert is an early detection screening that spots bleeding and non-bleeding tumors through tumor DNA analysis. ColoAlert analyzes samples for the four tumor markers associated with cancer: KRAS-mutation, BRAF-mutation, total amount of human DNA and occult blood. By analyzing tumor DNA, Mainz says ColoAlert detects 85% of colorectal cancer cases, often in the very early stages of the disease. Based on recent trials, Mainz Biomed says ColoAlert’s sensitivities exceeded 90% for detecting colorectal cancer and over 80% for advanced adenomas. Detecting advanced adenomas is crucial in preventing colorectal cancer, as identifying patients with these lesions allows for timely intervention through colonoscopy and adenoma removal, thereby averting cancer development, reports Mainz. Big Addressable Market It's a big market for Mainz Biomed to address, given colorectal cancer is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The U.S. Preventive Services Task Force recommends that screening with stool DNA tests be conducted once every three years, starting at age 45. As it stands, 71% of the diagnoses made are in the later stages of the disease. But if it's caught early, the survival rate after five years is 90%. Despite those favorable odds, only about four in ten colorectal cancers are spotted at the early stage. Each year in the U.S., 16.6 million colonoscopies are performed, yet about one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4 billion total market opportunity in the U.S., according to estimates compiled by Mainz Biomed. ColoAlert, if approved in the U.S., may help rectify that lack of timely screening. After all, Mainz Biomed says its detection system is less invasive than ColoGuard, the leading at-home test in the U.S., because it requires very small samples to test. It’s one of the reasons the company boasts 98% patient satisfaction in Germany. ColoAlert is also easy to use, which should be a big driver of adoption. Within five minutes your sample is collected and packaged and on the way to the lab. Patients receive a kit in the mail that includes instructions, a stool collector and a shipping label to return the kit to their local lab for testing. Patients receive the results in a few days. Mainz Biomed wants to bring its ColoAlert early cancer screening test to the U.S., and it is inking deals and readying clinical trials to achieve that. Its agreements with Quest Diagnostics put it one step closer. Stay tuned in 2025 – there may be lots more to come from Mainz Biomed on its path to commercializing ColoAlert in the U.S. and beyond. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 20, 2024 08:30 AM Eastern Standard Time

Image

Amesite Announces AI-Powered App Winning Enterprise Contracts In Growing Companies With Hundreds Of Franchise Owners – What’s Driving The Momentum?

Benzinga

By Meg Flippin, Benzinga The home healthcare market is in a state of flux. The need for home healthcare workers is soaring as the population in the U.S. ages. In about ten years, 78 million people in the U.S. will be 65 or over. By 2060, The Institute on Aging expects the demographic will increase to 98 million and account for a quarter of the U.S. population. At the same time, the nation is aging, there is a dearth of home healthcare workers, and it looks like it’s only going to get worse. Over the next decade, the institute expects the number of home health aide jobs to grow by 425,000, creating a shortage that will need to be filled. As it stands, about 95% of home and community-based care providers say they face moderate to severe staffing shortages, with 77% turning away new clients because of the lack of workers. What’s more, 72% of providers say staffing shortages make it hard to meet quality standards. If nothing is done, that problem will only get worse. It’s why some home healthcare providers are turning to technology, namely NurseMagic™, for an assist. The brainchild of Amesite (NASDAQ: AMST), NurseMagic is a proprietary AI-powered app designed for nurses and home health care workers. The company reports it has closed on contracts with franchise owners representing nationally recognized brands that operate hundreds of locations across the country – resulting in recurring revenue in a total addressable market it estimates at $330 billion. Streamlining Work, Improving Care The AI-powered app, which Amesite reports has seen explosive growth since its launch this past summer, provides nurses and home healthcare professionals with a handy tool that writes comprehensive documentation instantly, can quickly translate medical terms into easy-to-understand language, create work emails, assist nurses in talking to patients with compassion, coach nurses on taking effective breaks during the day, convert images to text, provide key information about medications and collect instant feedback. Amesite says its AI app integrates seamlessly into the operational frameworks of home care agencies, enhancing workflow efficiency and supporting employee retention by lightening administrative burdens and reducing worker burnout. As a result, AI technology can enable agencies to make the most of existing resources and extend care to more clients who would otherwise be turned away due to staffing constraints, reports Amesite. Take the Senior Helpers franchise in Northern Orange County for one example. Since adopting NurseMagic, owner Steven Nickens said NurseMagic has been empowering his staff to get answers to questions quickly through the app, saving time and ensuring accurate results. “NurseMagic's technology is transforming my organization with its intuitive and easy-to-use platform,” said Nickens. “NurseMagic is both powerful and incredibly easy to use, making it accessible to everyone on my team." Nickens isn’t alone in his assessment. Joshua Porter, owner of the Spokane North BrightStar Care franchise, said he uses NurseMagic to support the company’s rapid growth. "As a new franchise owner with extensive business and engineering experience, I’m thrilled to share how quickly we’re growing. When I discovered NurseMagic, I immediately recognized it as a must-have to stay competitive in today’s market,” said Porter, noting there are no hidden fees or messy contracts when bringing NurseMagic into the fray. Growth Driven By NurseMagic In addition to improving the quality of care for patients, NurseMagic is also aiming to help healthcare franchises grow their businesses. That’s certainly the case at the Fargo Senior Helpers franchise, with owner Tanya Ferber saying the app is enabling her to go after more medically complex clients in the new year. Plus, incorporating NurseMagic into her business attracts more tech-savvy healthcare workers. “It’s a value-added tool for my business and takes our quality to the next level,” says Ferber. It’s not just home healthcare franchises that benefit. Amesite says that by selling NurseMagic to franchise owners from well-known brands in the home health and home care industries, its revenue should grow and cement NurseMagic’s status as a must-have tool. “We made two tactical decisions: first, to build a best-in-class infrastructure that delivers top-tier compliance, security and low operating costs; and second, to price NurseMagic accessibly, at a sustainable margin, focusing on scaling sales rather than maximizing margins with a few customers,” said Dr. Ann Marie Sastry, CEO of Amesite. “These choices position us to meet the strong demand in our industry and drive widespread adoption.” Since launching NurseMagic a mere five months ago, the company says it has met several milestones, including launching a paid individual subscription, meeting HIPAA compliance requirements for paid enterprise customers and generating revenue in the home care market. The U.S. population is getting older at the same time that there is a shortage of nurses and home healthcare workers available to tend to the aging population. Those who are working are stressed and doing more with less. NurseMagic can fill that gap, presenting nurses, home health care workers and franchises with an AI-driven tool to improve the quality of life for workers and the care for patients, the company argues. It's a win-win, which is why Amesite has been hitting so many milestones in 2024, and expects revenue to ramp up in the new year. Featured photo by Dominik Lange on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

December 20, 2024 08:25 AM Eastern Standard Time

Image

Jaynike Pioneers Digital Transformation with Comprehensive Web Solutions

Rev Up Marketers

As digitalization reshapes global commerce and communication, Jaynike is redefining the standards of web design and digital marketing with its latest suite of enhanced services. Focused on empowering businesses to thrive in the competitive online landscape, Jaynike offers tailored solutions that combine cutting-edge technology with creativity to meet the unique needs of its diverse clientele. Recognizing that every business faces distinct challenges in the digital space, Jaynike offers responsive web design with targeted digital strategies, ensuring seamless user experiences and measurable outcomes. From startups seeking visibility to enterprises aiming to strengthen their digital footprint, Jaynike’s solutions are crafted to enable meaningful engagement with audiences. “At Jaynike, organization believe that a strong digital presence is more than just aesthetics—it’s about creating experiences that resonate and strategies that deliver,” said a spokesperson Named Richard Brown for Jaynike. “Approach is rooted in understanding each client’s vision and transforming it into impactful digital realities.” The enhanced services include state-of-the-art web development, advanced SEO strategies, content marketing, social media management, and precision-targeted advertising campaigns. By blending innovation with personalized attention, Jaynike positions itself as a trusted partner in navigating the complexities of digital transformation. With its customer-first philosophy and a steadfast commitment to excellence, Jaynike.com continues to pioneer advancements in web solutions, empowering businesses to connect, grow, and lead in the digital age. About Jaynike Jaynike is a leading provider of innovative web design and digital marketing solutions, dedicated to helping businesses excel in the digital era. Combining advanced technology with creative strategies, crafting tailored solutions to meet the unique needs. With a focus on measurable results and exceptional user experiences, Jaynike empowers businesses to build impactful online presences and achieve sustainable growth. Contact Details Jaynike Richard Brown support@jaynike.com Company Website https://www.jaynike.com

December 20, 2024 07:49 AM Eastern Standard Time

Image

Should You Still Buy Dogecoin Over $0.40? Here Are 2 Alternatives Under $1 With More Potential

Cutoshi

At this point, it would be surprising for Dogecoin (DOGE) not to reach $1 and beyond. The meme coin king continues to dominate the space as it cemented itself as a legitimate asset in the broader market. With that being said, there are other altcoins that could surpass Dogecoin in terms of ROI. While Tron (TRX) is an obvious example, a new arrival, Cutoshi (CUTO), could soon take the spotlight. Dogecoin Is Struggling To Breakout After Month-Long Consolidation When Donald Trump won the US presidency in early November, Dogecoin stunned the market with a triple-digit rally that saw its price multiply in the span of a few days. However, shortly after, Dogecoin began stalling as its momentum waned and selling pressure increased. After peaking at $0.47 Dogecoin (DOGE) entered a narrow trading channel with its price fluctuating around the $0.40 mark. On the other hand, whales continue to bolster their Dogecoin position in anticipation of a new rally. Analyst Ali Martinez has shared impressive on-chain numbers on X, highlighting a recent buying spree that saw large wallets spending over $64 million to purchase 160 million DOGE. In regards to Dogecoin’s price action, renowned DOGE bull KrissPax has highlighted a bull flag pattern on the chart. According to Kriss, a breakout above the trendline could propel Dogecoin to $0.69 by the end of the year. If this projection plays out, the prophesied $1 DOGE could become a reality in Q1 2025. Tron Is Retesting Lower Levels After ATH Run Tron (TRX) has been in up-only mode since bottoming out in 2022. In late 2024, Tron entered escape velocity as it tore through major resistance levels with ease and reached a new all-time high for the first time since 2018. However, after tagging the $0.42 peak, Tron’s price started to decline as bears stepped in. At press time, Tron trades at $0.28 following a 6.1% intraday decrease which was accompanied by an 18.8% decline in 24-hour volume, with roughly $1.88 billion worth of TRX traded across exchange platforms. However, analyst Anni Sarahayu points out on X that a Tron is printing a string of higher lows on the 4-hour chart. This teases an incoming breakout which could send Tron soaring to new heights by the end of December. At $24.7 billion, Tron’s market cap is worth less than half of Dogecoin's $60 billion, meaning that investors looking for projects with a proven track record and much greater room for growth could consider adding TRX to their portfolio. However, there could be an even better option. Cutoshi’s Farming Mechanism Is Turning Heads Cutoshi is already making waves with its hybrid framework that merges meme lore with DeFi functionality, creating the first-ever MemeFi ecosystem. The project is centered around CUTO DEX, a cross-chain, fully private, decentralized exchange that could soon give established protocols like Uniswap or Rayidium, a run for their money. Investors will be able to perform lightning-fast transactions on all major blockchains at some of the lowest fees on the market. Japanese Lucky Cats are said to bring prosperity to businesses. Cutoshi brings good fortune to the blockchain. Cutoshi Farming is one of the platform’s most intriguing features. Users will have the opportunity to earn massive prizes while growing their $CUTO portfolio. They will be tasked with completing fun missions aimed at expanding Cutoshi’s online reach. In exchange for their efforts, they will receive CUTO points which can be redeemed for more $CUTO once the token hits the markets. Moreover, a staking option will soon be available as well, allowing holders to put their $CUTO to work and tap into a passive income stream. Stage 4 of the presale is now live and over $1.37 million has been raised so far. $CUTO sells for just $0.031, making this the perfect entry point for early adopters who want to capitalize on this new DeFi-driven meme coin. For more information on the Cutoshi (CUTO) Presale: https://cutoshi.com/ Join and become a community member: https://twitter.com/CutoshiToken https://t.me/cutoshi Welcome to Cutoshi, the revolutionary meme coin, DeFi hub and educational platform inspired by the Lucky Cat and Satoshi Nakamoto’s teachings. Traditionally, people put the Lucky Cat in their homes and businesses to maximize its lucky powers and bring them good fortune and wealth. Now Cutoshi the Lucky Cat is on the blockchain bringing luck, prosperity, and wealth to your digital assets. Cutoshi is creating a path to financial freedom, for those who choose to honor the power of the Lucky Cat. Supporting the principles of freedom, privacy, anonymity, and monetary empowerment for the masses. Cutoshi aims to bring the benefits of blockchain to everyone. The regulatory environment surrounding cryptocurrencies is evolving and varies across jurisdictions. It is your responsibility to ensure compliance with applicable laws and regulations in your country or region before engaging with Custoshi. Contact Details Cutoshi hello@cutoshi.com Company Website https://cutoshi.com/

December 20, 2024 07:45 AM Eastern Standard Time

Image

1 2 3 4 5 ... 3786